Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma

Publisher： Karger

E-ISSN： 1423-0232|68|2-3|146-153

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.2-3, 2005-07, pp. : 146-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma

By  

Oncology, Vol. 70, Iss. 6, 2007-02 ,pp. : 411-417

Karger

Access to resources Recommend Favorite

Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 539-546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab

By  

Oncology Research and Treatment, Vol. 29, Iss. 3, 2006-03 ,pp. : 90-92

Karger

Access to resources Recommend Favorite